China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
Chinese biotech deal making is moving beyond the licensing of individual drug candidates, as the country transforms from a follower to a global innovation leader, according to analysts. The latest transaction underscores that shift. Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US…
China's biotech firms are increasingly moving up the value chain by forming more significant drug development partnerships, according to analysts. This shift is evident in the latest deal between Chinese cancer drug developer InnoCare Pharma and US pharmaceutical giant Eli Lilly, which could be worth up to US$3.35 billion. This trend reflects China's transformation from a follower to a global innovation leader in biotechnology, as the country moves away from simply licensing individual drug candidates and towards co-development arrangements and broader platform partnerships.
Analysts note that China's biotech sector is now generating innovative drug research at a higher quantity and quality, with recent deals like InnoCare's collaboration with Eli Lilly and Jiangsu Hengrui Pharmaceutical's agreement with Bristol Myers Squibb demonstrating this shift.
Brief written by urgent.news from South China Morning Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
